Rockefeller Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43.4M | Buy |
274,266
+38,434
| +16% | +$5.2M | 0.07% | 268 |
|
|
2026
Q1 | $30.1M | Sell |
235,832
-225
| -0.1% | -$28.1K | 0.05% | 331 |
|
|
2025
Q4 | $28.8M | Buy |
236,057
+72,636
| +44% | +$8.33M | 0.05% | 342 |
|
|
2025
Q3 | $16.4M | Sell |
163,421
-7,333
| -4% | -$660K | 0.03% | 477 |
|
|
2025
Q2 | $14.2M | Sell |
170,754
-767
| -0.4% | -$61.2K | 0.03% | 497 |
|
|
2025
Q1 | $13.9M | Sell |
171,521
-21,124
| -11% | -$1.89M | 0.03% | 466 |
|
|
2024
Q4 | $17.3M | Buy |
192,645
+14,142
| +8% | +$1.37M | 0.04% | 382 |
|
|
2024
Q3 | $17.6M | Buy |
178,503
+52,525
| +42% | +$5.16M | 0.05% | 380 |
|
|
2024
Q2 | $11.7M | Buy |
125,978
+11,524
| +10% | +$1.03M | 0.03% | 463 |
|
|
2024
Q1 | $10.9M | Buy |
114,454
+12,950
| +13% | +$1.2M | 0.03% | 476 |
|
|
2023
Q4 | $9.06M | Buy |
101,504
+865
| +0.9% | +$64.2K | 0.03% | 484 |
|
|
2023
Q3 | $7.35M | Sell |
100,639
-5,442
| -5% | -$435K | 0.03% | 497 |
|
|
2023
Q2 | $8.83M | Buy |
106,081
+173
| +0.2% | +$14.5K | 0.03% | 469 |
|
|
2023
Q1 | $8.07M | Sell |
105,908
-165,110
| -61% | -$13.7M | 0.03% | 469 |
|
|
2022
Q4 | $22.5M | Buy |
271,018
+175,429
| +184% | +$14.2M | 0.11% | 204 |
|
|
2022
Q3 | $7.58M | Buy |
95,589
+11,525
| +14% | +$972K | 0.04% | 434 |
|
|
2022
Q2 | $6.24M | Buy |
84,064
+5,482
| +7% | +$412K | 0.03% | 456 |
|
|
2022
Q1 | $7.06M | Buy |
78,582
+30,323
| +63% | +$2.8M | 0.03% | 458 |
|
|
2021
Q4 | $5.4M | Buy |
48,259
+13,918
| +41% | +$1.68M | 0.03% | 517 |
|
|
2021
Q3 | $4.32M | Buy |
34,341
+16,224
| +90% | +$2.09M | 0.02% | 511 |
|
|
2021
Q2 | $2.45M | Buy |
18,117
+8,022
| +79% | +$1.05M | 0.01% | 661 |
|
|
2021
Q1 | $1.37M | Sell |
10,095
-49,372
| -83% | -$7.39M | 0.01% | 692 |
|
|
2020
Q4 | $8.37M | Buy |
59,467
+56,148
| +1,692% | +$7.19M | 0.06% | 247 |
|
|
2020
Q3 | $369K | Buy |
3,319
+715
| +27% | +$80.2K | ﹤0.01% | 873 |
|
|
2020
Q2 | $292K | Buy |
2,604
+1,100
| +73% | +$108K | ﹤0.01% | 855 |
|
|
2020
Q1 | $116K | Buy |
1,504
+204
| +16% | +$18.1K | ﹤0.01% | 978 |
|
|
2019
Q4 | $124K | Buy |
1,300
+800
| +160% | +$69.2K | ﹤0.01% | 905 |
|
|
2019
Q3 | $38K | Sell |
500
-2,992
| -86% | -$249K | ﹤0.01% | 1055 |
|
|
2019
Q2 | $306K | Buy |
+3,492
| New | +$298K | ﹤0.01% | 517 |
|
|
2019
Q1 | – | Sell |
-24,705
| Closed | -$1.77M | – | 1942 |
|
|
2018
Q4 | $1.77M | Buy |
+24,705
| New | +$1.99M | 0.03% | 196 |
|
|
2018
Q3 | – | Sell |
-1,365
| Closed | -$130K | – | 790 |
|
|
2018
Q2 | $130K | Buy |
+1,365
| New | +$125K | ﹤0.01% | 367 |
|
Other funds holding XBI
JFG
Rockefeller Capital Management's XBI Position: Q2 2026 in Review
Rockefeller Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q2 2026, buying an estimated $5.2M and bringing the position to 274,266 shares worth $43.4M. The position accounts for 0.07% of the portfolio, ranked #268.
Rockefeller Capital Management first reported a position in XBI in Q2 2018 and has held it in 31 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Rockefeller Capital Management held 274,266 shares of State Street SPDR S&P Biotech ETF worth $43.4M as of Q2 2026.
- Rockefeller Capital Management bought 38,434 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $5.2M.
- State Street SPDR S&P Biotech ETF made up 0.07% of Rockefeller Capital Management's portfolio in Q2 2026, its #268 holding.
- Rockefeller Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 31 quarters since.
- 936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.